Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)
Center for Sight Las Vegas
Summary
The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.
Description
The study is a prospective single-practice with multiple locations, single-surgeon, parallel double arm study in subjects with open angle glaucoma (OAG), who were implanted with Hydrus microstent combined with cataract surgery to be randomized to receive Rocklatan vs. Comparator (artificial tears). Unmedicated MDIOP (mean diurnal intraocular pressure) measurements will be assessed at baseline (after Hydrus, prior to study medication) and at 1-month post-initiation of Study Drop.
Eligibility
- Age range
- 40+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 40 years and older * Subjects who have mild to moderate Open Angle Glaucoma (OAG) * Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \> 3 months prior to screening and within the last 2 years * Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications) * Unmedicated or washed out IOP range between 16-26 mmHg Exclusion Criteria: * History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microste…
Interventions
- DrugRocklatan (netarsudil 0.02% and latanoprost 0.005%)
Additional intraocular eye pressure lowering post-Hydrus
- DrugSystane
Placebo Comparator (artificial tears)
Location
- Center for SightLas Vegas, Nevada